Thompson Siegel & Walmsley LLC Takes Position in BioHarvest Sciences Inc. $BHST

Thompson Siegel & Walmsley LLC bought a new stake in shares of BioHarvest Sciences Inc. (NASDAQ:BHST) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 374,717 shares of the company’s stock, valued at approximately $1,945,000. Thompson Siegel & Walmsley LLC owned approximately 2.28% of BioHarvest Sciences at the end of the most recent reporting period.

Separately, Geode Capital Management LLC purchased a new position in shares of BioHarvest Sciences during the 4th quarter valued at approximately $61,000.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on BHST. Roth Mkm began coverage on BioHarvest Sciences in a research report on Thursday, February 19th. They set a “buy” rating and a $10.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of BioHarvest Sciences in a research note on Friday, March 27th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $10.00.

BioHarvest Sciences Stock Down 2.2%

Shares of BHST opened at $3.62 on Wednesday. BioHarvest Sciences Inc. has a 52-week low of $3.57 and a 52-week high of $12.80. The company has a market capitalization of $71.01 million, a PE ratio of -6.14 and a beta of 0.70. The stock has a fifty day simple moving average of $4.16 and a two-hundred day simple moving average of $4.89. The company has a quick ratio of 2.44, a current ratio of 2.96 and a debt-to-equity ratio of 0.03.

BioHarvest Sciences (NASDAQ:BHST) last issued its earnings results on Thursday, May 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. BioHarvest Sciences had a negative return on equity of 76.03% and a negative net margin of 32.54%.The business had revenue of $8.51 million during the quarter, compared to the consensus estimate of $8.50 million. As a group, equities analysts forecast that BioHarvest Sciences Inc. will post -0.45 EPS for the current year.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.